Complement 3 Glomerulopathy (C3G)
Complement 3 Glomerulopathy (C3G) Market

Complement 3 Glomerulopathy (C3G) is a group of rare kidneys diseases that are driven by dysregulation of the complement cascade. It is a type of glomerular disease, which is characterized by predominant C3 complement component (C3) deposits in the glomeruli in the absence of a major amount of immunoglobulin and without deposition of C1q and C4. 


The term C3G covers the dense deposit disease (DDD) and C3 glomerulonephritis (C3GN) that are the two patterns of damage and inflammation in the glomeruli. In other words, the damage and inflammation in the kidney tissue in DDD appear different from that in C3GN when seen under a microscope. People with DDD generally present at a younger age (childhood or adolescence) as compared to people with C3GN (adulthood).


Complement 3 Glomerulopathy Epidemiological Segmentation 

The Epidemiological Segmentation of Complement 3 Glomerulopathy in 7MM from 2017 to 2030 is segmented as:- 

  • Total Diagnosed Prevalent Population of Complement 3 Glomerulopathy (C3G)
  • Type-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy (C3G)
  • Age-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy (C3G)


Complement 3 Glomerulopathy Epidemiology 

  • The total diagnosed prevalent population of C3G in 7MM in 2017 was 8,175  
  • The diagnosed prevalent cases of C3G in 2017 in the United States were 3,967  


Complement 3 Glomerulopathy Market

The market size of C3G in 7MM in 2017 was USD 40.6 Million  


Complement 3 Glomerulopathy Market Drivers

  • Intermediate Pipeline Activity
  • Increase in Awareness
  • The advent of Biomarkers in Near Future

 

Complement 3 Glomerulopathy Market Barriers

  • Hurdles in Clinical Trial Settings
  • Drawbacks of Renal Replacement Therapy
  • Prone to Recurrence
  • The Dominance of off-label Therapies


Complement 3 Glomerulopathy Emerging Drugs

The emerging drugs of the Complement 3 Glomerulopathy market are 

  • Danicopan (ACH-4471/ALXN2040)
  • Narsoplimab (OMS721)
  • Pegcetacoplan (APL-2)
  • LNP023 (TBD)

 And many others. 


Complement 3 Glomerulopathy Key Players

The key players in the Complement 3 Glomerulopathy market are

  • Alexion Pharmaceuticals
  • Omeros Corporation
  • Apellis Pharmaceuticals
  • Novartis Pharmaceuticals

And many others.